BMY
Bristol-Myers Squibb Company
Revenue by product
2025, ended Dec 31, 2025
Earlier:
Products by fiscal year
| USDLine, in USD | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eliquis | 14.4B | 13.3B | — | 11.8B | 10.8B | 9.2B | 7.9B | 6.4B | 4.9B | 3.3B | 1.9B | 774M | 146M | 2.0M | — | — | — |
| Opdivo | 10.0B | 9.3B | — | 8.2B | 7.5B | 7.0B | 7.2B | 6.7B | 4.9B | 3.8B | 942M | 6.0M | — | — | — | — | — |
| Orencia | 3.71B | 3.68B | 3.60B | 3.46B | 3.31B | 3.16B | 2.98B | 2.71B | 2.48B | 2.27B | 1.89B | 1.65B | 1.44B | 1.18B | 0.92B | 0.73B | 0.60B |
| Breyanzi | 1.36B | 0.75B | 0.36B | 0.18B | 87M | — | — | — | — | — | — | — | — | — | — | — | — |
| Alliance and other revenues | 1.44B | — | 1.23B | 1.49B | 1.33B | — | — | — | — | — | — | — | — | — | — | — | — |
| Sprycel | 0.49B | 1.29B | 1.93B | — | — | 2.14B | 2.11B | 2.00B | 2.01B | 1.82B | 1.62B | 1.49B | 1.28B | 1.02B | 0.80B | 0.58B | 0.42B |
| Yervoy | 2.90B | 2.53B | 2.24B | 2.13B | 2.03B | 1.68B | 1.49B | 1.33B | 1.24B | 1.05B | 1.13B | 1.31B | 0.96B | 0.71B | 0.36B | — | — |
| Abecma | 427M | 406M | 472M | 388M | 164M | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Growth products | 1.92B | 1.64B | 1.21B | 1.09B | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Camzyos | 1.07B | 0.60B | 0.23B | 24M | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Opdivo Qvantig | 238M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Legacy products | 0.80B | 0.93B | 0.96B | 1.16B | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Sotyktu | 291M | 246M | 170M | 8.0M | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Krazati | 205M | 126M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other revenues | 992M | — | 620M | 746M | 614M | — | — | — | — | — | — | — | — | — | — | — | — |
| Alliance revenues | 447M | — | — | 742M | 716M | — | — | — | — | — | — | — | — | — | — | — | — |
| 7.4B | 13.5B | 32.0B | 14.7B | 19.8B | 19.4B | 4.4B | 3.3B | 5.2B | 7.2B | 9.1B | 10.6B | 12.6B | 14.7B | 19.2B | 18.2B | 17.8B | |
| Pomalyst/Imnovid | — | 3.55B | 3.44B | 3.50B | 3.33B | 3.07B | 0.32B | — | — | — | — | — | — | — | — | — | — |
| Cobenfy | — | 10M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth Portfolio | — | — | 19.4B | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Onureg | — | — | — | — | 73M | 17M | — | — | — | — | — | — | — | — | — | — | — |
| Recent LOE Products | — | — | — | — | 14.0B | — | — | — | — | — | — | — | — | — | — | — | — |
Reblozyl | 2.33B | 1.77B | 1.01B | 0.72B | — | 0.27B | — | — | — | — | — | — | — | — | — | — | — |
Opdualag | 1.19B | 0.93B | 0.63B | 0.25B | — | — | — | — | — | — | — | — | — | — | — | — | — |
Revlimid | 3.0B | 5.8B | 6.1B | 10.0B | 12.8B | 12.1B | 1.3B | — | — | — | — | — | — | — | — | — | — |
Zeposia | 577M | 566M | 434M | 250M | 134M | 12M | — | — | — | — | — | — | — | — | — | — | — |
Abraxane | 0.37B | 0.88B | 1.00B | — | 1.18B | 1.25B | 0.17B | — | — | — | — | — | — | — | — | — | — |
Inrebic | — | — | — | — | 74M | 55M | 5.0M | — | — | — | — | — | — | — | — | — | — |
| Mature and other brands | — | — | — | — | 2.23B | 2.22B | 2.29B | 2.36B | 3.95B | 2.27B | 3.82B | 3.40B | 4.88B | 5.78B | 2.95B | 3.17B | 3.65B |
| Empliciti | — | — | — | — | — | 381M | 357M | 247M | 231M | 150M | 3.0M | — | — | — | — | — | — |
| Baraclude | — | — | — | — | — | — | — | 0.74B | 1.05B | 1.19B | 1.31B | 1.44B | 1.53B | 1.39B | 1.20B | 0.93B | 0.73B |
| Sustiva Franchise | — | — | — | — | — | — | — | — | — | 1.07B | 1.25B | 1.44B | 1.61B | 1.53B | 1.49B | 1.37B | 1.28B |
| Reyataz | — | — | — | — | — | — | — | — | — | 0.91B | 1.14B | 1.36B | 1.55B | 1.52B | 1.57B | 1.48B | 1.40B |
| Hepatitis C Portfolio | — | — | — | — | — | — | — | — | — | 1.58B | 1.60B | 0.26B | — | — | — | — | — |
| Abilify | — | — | — | — | — | — | — | — | — | — | — | 2.02B | 2.29B | 2.83B | 2.76B | 2.57B | 2.59B |
| Erbitux | — | — | — | — | — | — | — | — | — | — | — | 723M | 696M | 702M | 691M | 662M | 683M |
| Diabetes Alliance | — | — | — | — | — | — | — | — | — | — | — | — | — | 972M | — | — | — |
| Onglyza Kombiglyze | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 473M | 158M | 24M |
| Avapro Avalide | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.95B | 1.18B | 1.28B |
| Plavix | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 7.09B | 6.67B | 6.15B |
| Nulojix | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 3.00M | — | — |
| Total | 48.2B | 48.3B | 45.0B | 46.2B | 46.4B | 42.5B | 26.1B | 22.6B | 20.8B | 19.4B | 16.6B | 15.9B | 16.4B | 17.6B | 21.2B | 19.5B | 18.8B |